Nrf2 upregulates the transcription of 3 main target genes in response to SFN and zymosan. by Doumet Georges Helou (7255823)

Induced expression of miR-146a decreases NF-κB activation. by Sakthi Priya Selvamani (607420)

“…(<b>C</b>) Western blot analysis of p- NF-κB (p65) and total NF-κB (p65) protein expression levels in primary human synovial fibroblasts transfected with 100 pm scrambled and 100 pm miR-146a mimics. Increase in miR-146a significantly decreases p- NF-κB (p65) levels compared to controls and scramble miR-146a. …”

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

<i>In vivo</i> HDL protects the heart from IR injury via STAT3 activation. by Sarah Pedretti (703288)

Fig 5 - by Harshita Sharma (4836180)

Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

Physiological characterization of rice <i>m167</i> plants. by Xuexia Wang (3701098)

AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

Metformin inhibits glutaminase activity in a dose dependent manner: from 17.5% at 10 mM up to 68% at 100 mM (A) (* p<0.05). by M. Mar Díaz-Herrero (646639)

Gut microbiota modulates fecal metabolomic profiles in Atm-KO and WT mice. by Amrita K. Cheema (515119)

Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

Low doses of S100A14 stimulate cell proliferation and promote cell survival. by Qing'e Jin (222695)

“…(<b>I</b>) 10 µg/ml S100A14 decreased the percentage of sub-G1 phase of KYSE180 cells with the treatment of Dox (0.5 µM, 48 h). …”

Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

Overtrained mice show reduced signaling capacity of DLS mGluR1/5 in response to a change in the prevailing A–O contingency. by Vincent Paget-Blanc (21807763)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects: